Eli Lilly and Company (LLY)vsEchoStar Corporation (SATS)
LLY
Eli Lilly and Company
$948.45
-2.72%
HEALTHCARE · Cap: $869.41B
SATS
EchoStar Corporation
$127.15
+3.69%
COMMUNICATION SERVICES · Cap: $36.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 381% more annual revenue ($72.25B vs $15.00B). LLY leads profitability with a 35.0% profit margin vs -96.6%. SATS appears more attractively valued with a PEG of 1.34. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
SATS
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+66.0%
Fair Value
$323.23
Current Price
$127.15
$196.08 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 108 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 27.2x book value
Weak financial health signals
ROE of -111.3% — below average capital efficiency
Revenue declined 4.3%
Earnings declined 85.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : SATS
PEG of 1.34 suggests the stock is reasonably priced for its growth.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : SATS
The primary concerns for SATS are Piotroski F-Score, Return on Equity, Revenue Growth. Debt-to-equity of 4.40 is elevated, increasing financial risk.
Key Dynamics to Monitor
LLY profiles as a growth stock while SATS is a turnaround play — different risk/reward profiles.
SATS carries more volatility with a beta of 0.96 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 34/100), backed by strong 35.0% margins and 55.5% revenue growth. SATS offers better value entry with a 66.0% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →EchoStar Corporation
COMMUNICATION SERVICES · TELECOM SERVICES · USA
EchoStar Corporation provides broadband satellite technologies and broadband Internet services. The company is headquartered in Englewood, Colorado.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?